Targeted oncology vaccines XEME Biopharma operates in clinical-stage cancer immunotherapy with personalized autologous vaccines and two lead products (Oncoquest™-CLL and Oncoquest™-L). This presents opportunities to discuss partnership or trials with oncology centers seeking novel vaccine platforms for leukemia and lymphoma.

Disruptive manufacturing Leverage Aggregon® technology for rapid manufacturing (less than 24 hours) and low per-dose costs to position as a cost-efficient, scalable vaccine solution for healthcare providers and payers exploring faster time-to-treatment in cancer care.

High margin potential The platform offers very low production costs with high margins, a compelling selling point when engaging investors, contract manufacturers, and potential collaborators aiming to optimize profitability in personalized cancer vaccines.

Early-stage resource needs With a small team and pre-commercial revenue, focus sales efforts on strategic partnerships, licensing discussions, CROs, and academic collaborations to accelerate clinical development and market entry.

Market readiness signals The broad applicability of personalized and off-the-shelf possibilities along with rapid manufacturing suggests opportunities to pair with hospitals, specialty clinics, and biotech ecosystems pursuing innovative immunotherapy platforms.